A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects

NCT02632526 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Male Subjects
Cardiovascular Disease

Interventions

DRUG: AZD5718 oral suspension crystalline form (1 to 100 mg/mL) (Part A)
DRUG: AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part A)
DRUG: AZD5718 placebo oral suspension
DRUG: AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part B)

Sponsor

AstraZeneca